Outset Medical prelim Q3 rev $30.4M (+9% YoY); FY23 guidance cut to ~$130M on FDA letter headwind

Outset Medical, Inc.

2023-Q3 EPS reported -$2.72 revenue$99,869,000

Preliminary Q3 revenue $30.4M (+9% YoY), gross margin 23.6% (25.6% non-GAAP).
FY23 revenue guidance lowered to ~$130M, citing FDA warning letter impact and cautious capex outlook.
Cash and investments $197M as of Sept. 30, 2023.
CEO notes no deal losses but headwinds expected into Q4; confidence in long-term growth and profitability.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Outset Medical, Inc. updated its third quarter ended Sept. 30, 2023 guidance (reaffirmed).

Period: third quarter ended Sept. 30, 2023
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

On October 12, 2023, Outset Medical, Inc. (the “ Company ”) issued a press release announcing expected revenue and gross margin for the third quarter ended September 30, 2023, as well as updated financial guidance for 2023 revenue.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Outset Medical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-053108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.